Skip to content
Sign up to receive our free weekday morning edition, and you'll never miss a scoop.
A majority of K Street leaders say a third reconciliation bill is unlikely to pass the 119th Congress, according to our latest Canvass survey.

K St: Third reconciliation bill is unlikely

A majority of K Street leaders say a third reconciliation bill is unlikely to pass the 119th Congress, according to our latest Canvass survey.

Despite the pessimism, most respondents say supplemental military funding for the war in Iran (79%) and taxes (51%) would be addressed in such a package.

Where it stands. A third reconciliation bill could include hundreds of billions of dollars in defense funding. House Budget Committee Chair Jodey Arrington (R-Texas) said he wants to pass the reconciliation package before the August recess.

Arrington also said he wants to cut “fraud” and include provisions to make housing and health care more affordable.

K Street respondents are more optimistic about a second reconciliation bill, with 88% of respondents saying a package would pass.

Senate Republicans were set to pass the roughly $70 billion package to fund ICE and CBP before recess, but President Donald Trump’s $1.8 billion “anti-weaponization” fund drew GOP blowback and derailed the bill.

The Canvass K Street was conducted May 4-22 in partnership with independent public affairs firm, LSG.

Want to take part in The Canvass? Our survey provides anonymous monthly insights from top Capitol Hill staffers and K Street leaders on key issues facing Washington.

Don’t miss out on your chance to weigh in! Sign up here if you work on K Street. Click here to sign up if you’re a senior congressional staffer.

Presented by Cencora

From accelerating innovation to powering the pharmaceutical supply chain, we reduce barriers to expand access to medications for millions of Americans at sites of care in their communities. Learn more

Editorial photos provided by Getty Images. Political ads courtesy of AdImpact.

Presented by Cencora

From accelerating innovation to powering the pharmaceutical supply chain, we reduce barriers to expand access to medications for millions of Americans at sites of care in their communities. Learn more

Welcome to Punchbowl News AM! We're glad to have you here.

Want to get more of what you need? Share a bit more about yourself to help us tailor your reader experience.

Thank you for signing up!

Thank you for signing up!

 

We have sent you a confirmation email. Please follow the provided instructions to complete your sign-up.

Thank you for confirming! You are now subscribed to the Punchbowl News AM list.

You're subscribed! Welcome to the community.